↓ Skip to main content

Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Overview of attention for article published in Neurology, December 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#6 of 12,481)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
112 news outlets
blogs
4 blogs
twitter
236 tweeters
facebook
13 Facebook pages
wikipedia
2 Wikipedia pages
googleplus
1 Google+ user

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
149 Mendeley
citeulike
1 CiteULike
Title
Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
Published in
Neurology, December 2017
DOI 10.1212/wnl.0000000000004826
Pubmed ID
Authors

Ronald C. Petersen, Oscar Lopez, Melissa J. Armstrong, Thomas S.D. Getchius, Mary Ganguli, David Gloss, Gary S. Gronseth, Daniel Marson, Tamara Pringsheim, Gregory S. Day, Mark Sager, James Stevens, Alexander Rae-Grant

Abstract

To update the 2001 American Academy of Neurology (AAN) guideline on mild cognitive impairment (MCI). The guideline panel systematically reviewed MCI prevalence, prognosis, and treatment articles according to AAN evidence classification criteria, and based recommendations on evidence and modified Delphi consensus. MCI prevalence was 6.7% for ages 60-64, 8.4% for 65-69, 10.1% for 70-74, 14.8% for 75-79, and 25.2% for 80-84. Cumulative dementia incidence was 14.9% in individuals with MCI older than age 65 years followed for 2 years. No high-quality evidence exists to support pharmacologic treatments for MCI. In patients with MCI, exercise training (6 months) is likely to improve cognitive measures and cognitive training may improve cognitive measures. Clinicians should assess for MCI with validated tools in appropriate scenarios (Level B). Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms (Level B). Clinicians should monitor cognitive status of patients with MCI over time (Level B). Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated (Level B). Clinicians may choose not to offer cholinesterase inhibitors (Level B); if offering, they must first discuss lack of evidence (Level A). Clinicians should recommend regular exercise (Level B). Clinicians may recommend cognitive training (Level C). Clinicians should discuss diagnosis, prognosis, long-term planning, and the lack of effective medicine options (Level B), and may discuss biomarker research with patients with MCI and families (Level C).

Twitter Demographics

The data shown below were collected from the profiles of 236 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 149 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 148 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 25 17%
Other 20 13%
Researcher 17 11%
Student > Master 15 10%
Unspecified 14 9%
Other 58 39%
Readers by discipline Count As %
Medicine and Dentistry 74 50%
Unspecified 22 15%
Neuroscience 19 13%
Psychology 16 11%
Engineering 5 3%
Other 13 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 1065. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2018.
All research outputs
#2,627
of 12,150,851 outputs
Outputs from Neurology
#6
of 12,481 outputs
Outputs of similar age
#201
of 335,202 outputs
Outputs of similar age from Neurology
#2
of 207 outputs
Altmetric has tracked 12,150,851 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,481 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,202 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 207 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.